JP6779785B2 - ヒトメソテリンキメラ抗原受容体およびその使用 - Google Patents

ヒトメソテリンキメラ抗原受容体およびその使用 Download PDF

Info

Publication number
JP6779785B2
JP6779785B2 JP2016541055A JP2016541055A JP6779785B2 JP 6779785 B2 JP6779785 B2 JP 6779785B2 JP 2016541055 A JP2016541055 A JP 2016541055A JP 2016541055 A JP2016541055 A JP 2016541055A JP 6779785 B2 JP6779785 B2 JP 6779785B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541055A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500869A (ja
JP2017500869A5 (OSRAM
Inventor
グレゴリー・ビーティ
ボリス・エンヘルス
ニーラジャ・イダマカンティ
カール・エイチ・ジューン
アンドレアス・レーヴ
ソン・ホイジュエン
チーロン・ウー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア filed Critical ノバルティス アーゲー
Publication of JP2017500869A publication Critical patent/JP2017500869A/ja
Publication of JP2017500869A5 publication Critical patent/JP2017500869A5/ja
Priority to JP2020173461A priority Critical patent/JP6987945B2/ja
Application granted granted Critical
Publication of JP6779785B2 publication Critical patent/JP6779785B2/ja
Priority to JP2021195532A priority patent/JP2022046476A/ja
Priority to JP2023126889A priority patent/JP2023159154A/ja
Priority to JP2024012531A priority patent/JP7797549B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
JP2016541055A 2013-12-19 2014-12-19 ヒトメソテリンキメラ抗原受容体およびその使用 Active JP6779785B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020173461A JP6987945B2 (ja) 2013-12-19 2020-10-14 ヒトメソテリンキメラ抗原受容体およびその使用
JP2021195532A JP2022046476A (ja) 2013-12-19 2021-12-01 ヒトメソテリンキメラ抗原受容体およびその使用
JP2023126889A JP2023159154A (ja) 2013-12-19 2023-08-03 ヒトメソテリンキメラ抗原受容体およびその使用
JP2024012531A JP7797549B2 (ja) 2013-12-19 2024-01-31 ヒトメソテリンキメラ抗原受容体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2013089979 2013-12-19
CNPCT/CN2013/089979 2013-12-19
CNPCT/CN2014/082610 2014-07-21
CN2014082610 2014-07-21
CNPCT/CN2014/090509 2014-11-06
CN2014090509 2014-11-06
PCT/CN2014/094393 WO2015090230A1 (en) 2013-12-19 2014-12-19 Human mesothelin chimeric antigen receptors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020173461A Division JP6987945B2 (ja) 2013-12-19 2020-10-14 ヒトメソテリンキメラ抗原受容体およびその使用

Publications (3)

Publication Number Publication Date
JP2017500869A JP2017500869A (ja) 2017-01-12
JP2017500869A5 JP2017500869A5 (OSRAM) 2018-02-01
JP6779785B2 true JP6779785B2 (ja) 2020-11-04

Family

ID=53402126

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016541055A Active JP6779785B2 (ja) 2013-12-19 2014-12-19 ヒトメソテリンキメラ抗原受容体およびその使用
JP2020173461A Active JP6987945B2 (ja) 2013-12-19 2020-10-14 ヒトメソテリンキメラ抗原受容体およびその使用
JP2021195532A Pending JP2022046476A (ja) 2013-12-19 2021-12-01 ヒトメソテリンキメラ抗原受容体およびその使用
JP2023126889A Withdrawn JP2023159154A (ja) 2013-12-19 2023-08-03 ヒトメソテリンキメラ抗原受容体およびその使用
JP2024012531A Active JP7797549B2 (ja) 2013-12-19 2024-01-31 ヒトメソテリンキメラ抗原受容体およびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020173461A Active JP6987945B2 (ja) 2013-12-19 2020-10-14 ヒトメソテリンキメラ抗原受容体およびその使用
JP2021195532A Pending JP2022046476A (ja) 2013-12-19 2021-12-01 ヒトメソテリンキメラ抗原受容体およびその使用
JP2023126889A Withdrawn JP2023159154A (ja) 2013-12-19 2023-08-03 ヒトメソテリンキメラ抗原受容体およびその使用
JP2024012531A Active JP7797549B2 (ja) 2013-12-19 2024-01-31 ヒトメソテリンキメラ抗原受容体およびその使用

Country Status (14)

Country Link
US (4) US10640569B2 (OSRAM)
EP (2) EP4026909A1 (OSRAM)
JP (5) JP6779785B2 (OSRAM)
CN (2) CN116478927A (OSRAM)
AU (3) AU2014366047B2 (OSRAM)
BR (1) BR112016013187A2 (OSRAM)
CA (3) CA3225453A1 (OSRAM)
ES (1) ES2918501T3 (OSRAM)
IL (1) IL245764A0 (OSRAM)
MX (1) MX2016008076A (OSRAM)
RU (1) RU2714902C2 (OSRAM)
SG (1) SG11201604815RA (OSRAM)
TW (1) TWI672379B (OSRAM)
WO (1) WO2015090230A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046476A (ja) * 2013-12-19 2022-03-23 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP4303229A3 (en) * 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP4406610A3 (en) 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
ES2928000T3 (es) 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3183268B1 (en) 2014-08-19 2020-02-12 Novartis AG Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20250067191A (ko) * 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
HK1245326A1 (zh) 2014-12-12 2018-08-24 Voyager Therapeutics, Inc. 用於生产scaav的组合物和方法
US20190054117A1 (en) * 2014-12-19 2019-02-21 Novartis Ag Dimerization switches and uses thereof
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
CN109476722A (zh) 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
WO2017032293A1 (zh) * 2015-08-21 2017-03-02 科济生物医药（上海）有限公司 抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
US11890301B2 (en) 2015-08-28 2024-02-06 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
US11649435B2 (en) 2015-08-28 2023-05-16 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
ES2778651T3 (es) * 2015-10-09 2020-08-11 Miltenyi Biotec Technology Inc Receptores de antígeno quimérico y métodos de uso
NZ782855A (en) 2015-12-04 2025-08-29 Novartis Ag Compositions and methods for immunooncology
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
EP3397755B1 (en) 2015-12-28 2024-11-06 Novartis AG Methods of making chimeric antigen receptor -expressing cells
MX2018008106A (es) 2015-12-30 2019-03-14 Novartis Ag Terapias con celulas inmunoefectoras de una eficacia mejorada.
CN108934158B (zh) * 2016-02-01 2022-11-15 Gc细胞治疗 细胞冻存用培养基组合物及其应用
US20200281973A1 (en) 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
DK3443096T5 (da) 2016-04-15 2024-09-09 Novartis Ag Sammensætninger og fremgangsmåder til selektiv ekspression af kimære antigenreceptorer
US11400116B2 (en) * 2016-05-06 2022-08-02 The Regents Of The University Of California Systems and methods for targeting cancer cells
US20210054068A1 (en) * 2016-06-08 2021-02-25 The Board Of Trustees Of The Leland Stanford Junior University Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody
EP3476865B1 (en) * 2016-06-28 2023-09-13 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Method for constructing pd-1 gene-modified humanized animal model and use thereof
KR101897464B1 (ko) * 2016-07-14 2018-09-13 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
WO2018012895A1 (ko) * 2016-07-14 2018-01-18 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
SG11201900344YA (en) * 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
CA3032581A1 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201901184QA (en) 2016-08-12 2019-03-28 Toolgen Inc Manipulated immunoregulatory element and immunity altered thereby
CN107840891A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗msln抗体及其应用
WO2018064387A1 (en) 2016-09-28 2018-04-05 Novartis Ag Porous membrane-based macromolecule delivery system
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
CN107286247B (zh) * 2016-12-28 2019-09-03 时力生物科技（北京）有限公司 含抗间皮素单链抗体的嵌合抗原受体修饰的树突状细胞及其用途
CA3049252C (en) * 2017-01-09 2020-11-24 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
EP3388073A1 (en) * 2017-04-12 2018-10-17 polybliocept GmbH Targeting mesothelin in brain cancer
CN110914431B (zh) * 2017-05-08 2024-04-19 株式会社图尔金 经人工操纵的免疫细胞
CN109797171A (zh) * 2017-05-08 2019-05-24 北京东方略细胞技术有限公司 经修饰的t细胞、其制备方法及用途
AU2018269194B2 (en) * 2017-05-15 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
JP7164598B2 (ja) * 2017-05-17 2022-11-01 サンダー・バイオテック・インコーポレイテッド トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
CN109306014B (zh) * 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
WO2019028174A2 (en) 2017-08-02 2019-02-07 Lilac Solutions, Inc. Ion exchange system for lithium extraction
CN109553686A (zh) 2017-09-26 2019-04-02 南京安吉生物科技有限公司 一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
CN109586842B (zh) * 2017-09-29 2022-10-11 北京紫光展锐通信技术有限公司 Pdcch的配置方法及装置、译码方法及装置、介质、设备
CN109593721B (zh) * 2017-09-30 2022-11-01 亘喜生物科技（上海）有限公司 具有自杀基因开关的靶向人间皮素的工程化免疫细胞
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
JP6339283B1 (ja) 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
CA3087147A1 (en) * 2017-12-27 2019-07-04 Takeda Pharmaceutical Company Limited Nucleic acid-containing lipid nano-particle and use thereof
CN109971714B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 自表达pd-1抗体并靶向间皮素的嵌合抗原受体修饰t细胞及其用途
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
CA3086832A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP4006153B1 (en) 2018-01-12 2024-07-03 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
CA3090249A1 (en) * 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN116763943A (zh) * 2018-08-07 2023-09-19 普渡研究基金会 使car t细胞恢复活力
AU2019318135A1 (en) * 2018-08-10 2021-03-04 Sangamo Therapeutics France New car constructs comprising TNFR2 domains
US11932698B2 (en) 2018-08-29 2024-03-19 Nanjing Legend Biotech Co., Ltd. Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
EP4635978A2 (en) 2018-08-31 2025-10-22 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US12454694B2 (en) 2018-09-07 2025-10-28 Beam Therapeutics Inc. Compositions and methods for improving base editing
AU2019343184A1 (en) * 2018-09-20 2021-04-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7634924B2 (ja) * 2018-10-18 2025-02-25 武田薬品工業株式会社 Ｔ細胞の活性化／増殖方法
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN109679871A (zh) * 2019-01-08 2019-04-26 西北民族大学 一种pam-sa固定化微生物降解含油废水的方法
KR102070016B1 (ko) * 2019-01-21 2020-01-29 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
PT3920939T (pt) * 2019-02-08 2025-01-08 Biontech Cell & Gene Therapies Gmbh Células modificadas com recetor de antigénio quimérico para o tratamento de cancros que expressam cldn6
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
AU2020229806A1 (en) 2019-02-25 2021-07-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020181221A1 (en) * 2019-03-07 2020-09-10 Children's Medical Center Corporation Targeted delivery of immune-modulating vhh and vhh-fusion protein
CN110055269B (zh) * 2019-03-20 2021-03-16 英威福赛生物技术有限公司 人间皮素嵌合抗原受体、其t细胞及其制备方法和用途
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
GB201909283D0 (en) 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
WO2021009701A1 (en) * 2019-07-17 2021-01-21 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
WO2021055437A1 (en) * 2019-09-16 2021-03-25 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
CN115103910A (zh) 2019-10-03 2022-09-23 工匠开发实验室公司 具有工程化的双引导核酸的crispr系统
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
JP7714545B2 (ja) 2019-11-26 2025-07-29 ノバルティス アーゲー キメラ抗原受容体及びその使用
BR112022011998A2 (pt) 2019-12-20 2022-08-30 Novartis Ag Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
MX2022007833A (es) * 2019-12-23 2022-09-23 Cellectis Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
JP2023534808A (ja) 2020-07-17 2023-08-14 インスティル バイオ （ユーケイ） リミテッド 養子細胞療法のための標的共刺激を提供する受容体
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2021245153B2 (en) * 2020-08-04 2022-06-30 Cellengene Inc Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
CA3188862A1 (en) 2020-08-20 2022-02-24 Carl Alexander Kamb Compositions and methods for treating mesothelin positive cancers
CN111948185B (zh) * 2020-08-21 2023-03-21 中国药科大学 基于二维扩增阵列模式的瞬时识别急性肾损伤发展进程的传感器、制备方法及用途和用法
CA3188978A1 (en) 2020-08-21 2022-02-24 Sandeep Tharian Koshy Compositions and methods for in vivo generation of car expressing cells
GB202018554D0 (en) 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022166365A1 (zh) * 2021-02-03 2022-08-11 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
AU2022220754A1 (en) * 2021-02-10 2023-08-17 Cartherics Pty. Ltd. Methods and compositions for generating stem cell-derived immune cells with enhanced function
WO2022182801A1 (en) 2021-02-25 2022-09-01 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3218362A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
EP4333983A4 (en) * 2021-05-07 2025-07-30 Kiromic Biopharma Inc MESOTHELIN ISOFORM-BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THEM AND USES THEREOF
AU2022279862B2 (en) * 2021-05-26 2024-02-29 Cellengene Inc Chimeric antigen receptor comprising anti-mesothelin scfv, and use thereof
EP4419672A2 (en) 2021-06-01 2024-08-28 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
TW202306997A (zh) 2021-06-16 2023-02-16 英商英斯特生物科技有限公司 用於在過繼細胞療法中提供標靶共刺激之受體
CA3223311A1 (en) 2021-06-18 2022-12-22 Andrea BARGHETTI Compositions and methods for targeting, editing or modifying human genes
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2023019396A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Mesothelin-targetting antibodies, chimeric antigen receptors, and uses thereof
US20250000973A1 (en) 2021-08-20 2025-01-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20230265147A1 (en) * 2021-09-17 2023-08-24 The Trustees Of The University Of Pennsylvania Interleukin-9 Signaling in Chimeric Antigen Receptor (CAR) Immune Cells
CA3232968A1 (en) 2021-10-14 2023-04-20 Jasper Williams Immune cells having co-expressed shrnas and logic gate systems
CN115991782A (zh) * 2021-10-18 2023-04-21 普米斯生物技术(珠海)有限公司 抗间皮素纳米抗体及其用途
CN116063532B (zh) * 2021-12-29 2023-11-07 华道(上海)生物医药有限公司 结合抗间皮素的抗体及其应用
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
US20250388896A1 (en) 2022-03-01 2025-12-25 Celyntra Therapeutics Sa Composition and methods for transgene insertion
EP4499260A1 (en) 2022-03-28 2025-02-05 Lilac Solutions, Inc. Devices for efficient sorbent utilization in lithium extraction
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024014470A1 (ja) * 2022-07-13 2024-01-18 国立大学法人大阪大学 腫瘍の予防および／または治療剤
EP4608983A1 (en) 2022-10-26 2025-09-03 Novartis AG Lentiviral formulations
KR102688113B1 (ko) * 2022-11-02 2024-07-29 주식회사 셀렌진 메소텔린에 대한 친화도가 상승된 키메릭 항원 수용체 및 이의 용도
CN116138212B (zh) * 2023-01-11 2024-03-05 江苏省中医院 一种制备细胞因子释放综合征小鼠模型的方法及应用
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025090583A1 (en) * 2023-10-23 2025-05-01 The Regents Of The University Of California Targeted delivery vehicles for endogenous cell engineering
CN117143825B (zh) * 2023-11-01 2024-01-23 上海兴瑞一达生物科技有限公司 一种msln嵌合抗原受体修饰的t细胞及其应用
WO2025145087A1 (en) * 2023-12-29 2025-07-03 Eureka Therapeutics, Inc. Constructs targeting msln peptide/mhc complexes and uses thereof
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
CN118667815B (zh) * 2024-07-16 2025-02-14 宁夏大学 一种靶向prdm1改善牛子宫内膜炎的核苷酸序列及其应用

Family Cites Families (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE3381783D1 (de) 1982-03-03 1990-09-13 Genentech Inc Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
ATE191218T1 (de) 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
WO1995030014A1 (en) 1994-05-02 1995-11-09 Ciba-Geigy Ag Bifunctional protein, preparation and use
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
DK0871495T3 (da) 1995-02-24 2005-10-17 Gen Hospital Corp Omdirigering af cellulær immunitet med receptorkimærer
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
ES2187660T3 (es) 1995-06-09 2003-06-16 Novartis Ag Derivados de rapamicina.
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1998018809A1 (en) 1996-10-25 1998-05-07 Cell Genesys, Inc. Targeted cytolysis of cancer cells
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
CA2319236A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
JP4843138B2 (ja) 1998-04-15 2011-12-21 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Ｔ細胞阻害性受容体組成物およびその使用
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
IL147442A0 (en) 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001243288B2 (en) 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
IL136511A0 (en) 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
CA2763913C (en) 2001-08-10 2014-10-28 Aberdeen University Antigen binding domains
ATE434040T1 (de) 2001-10-01 2009-07-15 Dyax Corp Mehrkettige eukaryontische display-vektoren und deren verwendungen
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7638326B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
GB0208104D0 (en) 2002-04-09 2002-05-22 Univ Dundee Method
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
AU2004255216B2 (en) 2003-07-01 2010-08-19 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
JP2007518399A (ja) 2003-12-02 2007-07-12 ジェンザイム コーポレイション 肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP3363907A1 (en) 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2006060878A1 (en) 2004-12-10 2006-06-15 Peter Maccallum Cancer Institute Methods and compositions for adoptive immunotherapy
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
NZ597168A (en) 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
UA116188C2 (uk) 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
WO2008121420A1 (en) 2007-03-30 2008-10-09 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
AU2008266951C1 (en) 2007-06-18 2025-06-19 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
HRP20150074T1 (hr) 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
EP2212350B1 (en) 2007-10-26 2013-08-28 Governing Council of the University of Toronto Treating chronic viral infection by targetting TIM-3
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
RU2010138647A (ru) 2008-02-21 2012-03-27 Астразенека Аб (Se) Комбинированная терапия 238
US8379824B2 (en) 2008-03-06 2013-02-19 At&T Intellectual Property I, Lp Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009266873A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc TGF-beta antagonist multi-target binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
WO2010027827A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
ES2961498T3 (es) 2008-08-26 2024-03-12 Hope City Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
WO2010030002A1 (ja) 2008-09-12 2010-03-18 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
KR20190069615A (ko) 2008-12-09 2019-06-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2389443B1 (en) 2009-01-23 2018-11-14 Roger Williams Hospital Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
AP2011005859A0 (en) 2009-02-23 2011-10-31 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to CD19 and their uses.
US8460660B2 (en) * 2009-03-24 2013-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
BRPI0925059A2 (pt) 2009-04-03 2015-07-28 S Bio Pte Ltd Pirimidina substituída de compostos de purina como quinase(s) inibidoras.
WO2010125571A1 (en) 2009-04-30 2010-11-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anti ceacam1 antibodies and methods of using same
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
WO2011041093A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
CN102134276A (zh) * 2010-01-22 2011-07-27 上海抗体药物国家工程研究中心有限公司 一种抗ctla-4嵌合抗体
EP2531216B1 (en) 2010-02-04 2019-03-27 The Trustees Of The University Of Pennsylvania Icos critically regulates the expansion and function of inflammatory human th17 cells
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
PH12013500064A1 (en) 2010-07-09 2013-03-11 Exelixis Inc Combinations of kinase inhibitors for the treatment of cancer
CN103108873A (zh) 2010-07-16 2013-05-15 皮拉马尔企业有限公司 作为激酶抑制剂的取代的咪唑并喹啉衍生物
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
NZ706016A (en) 2010-10-27 2016-10-28 Baylor College Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
AR084356A1 (es) 2010-12-20 2013-05-08 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2012099973A2 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
SG193591A1 (en) 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
EP3323833B1 (en) 2011-04-01 2019-12-04 Memorial Sloan-Kettering Cancer Center T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
NZ710810A (en) 2011-04-08 2016-09-30 Baylor College Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
AU2012240562B2 (en) 2011-04-08 2016-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
ES2990023T3 (es) 2011-07-25 2024-11-28 Nationwide Childrens Hospital Inc Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4
CN104114233B (zh) * 2011-07-29 2021-11-12 宾夕法尼亚大学董事会 转换共刺激受体
SG2014009492A (en) 2011-08-11 2014-09-26 Intellikine Llc Kinase inhibitor polymorphs
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
WO2013040577A1 (en) 2011-09-16 2013-03-21 The Research Foundation Of State University Of New York Aptamers resistant to nucleocapsid degradation
KR20140060541A (ko) 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
DK2755487T3 (en) 2011-09-16 2019-04-08 Baylor College Medicine TARGETATION OF THE TUMORMICROMY ENVIRONMENT USING MANIPULATED NKT CELLS
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
JP6385277B2 (ja) 2011-12-01 2018-09-05 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
CA3084919A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
WO2013126729A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
IN2014DN07414A (OSRAM) 2012-02-22 2015-04-24 Univ Pennsylvania
WO2013126720A2 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
WO2013126726A1 (en) * 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CA3209571A1 (en) * 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
AU2013289970A1 (en) 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating CAR T cells
MX382772B (es) 2012-07-13 2025-03-11 Univ Pennsylvania Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto.
PL4461308T3 (pl) 2012-07-13 2025-08-11 The Trustees Of The University Of Pennsylvania Kontrola toksyczności dla aktywności przeciwnowotworowej CAR
MX2015000426A (es) 2012-07-13 2015-07-14 Univ Pennsylvania Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
EP2872533B1 (en) 2012-07-13 2019-04-24 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
WO2014011993A2 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Epitope spreading associated with car t-cells
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
CN102775500A (zh) * 2012-08-03 2012-11-14 郑骏年 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
RS61345B1 (sr) 2012-08-20 2021-02-26 Hutchinson Fred Cancer Res Postupak i kompozicije za ćelijsku imunoterapiju
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
CN102875685B (zh) * 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
US9365641B2 (en) 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CA3201072A1 (en) 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
ES2576126T3 (es) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
BR122021008308B1 (pt) 2012-12-12 2022-12-27 The Broad Institute, Inc. Sistemas de componente crispr-cas, métodos e composições para manipulação de sequência
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
EP4406610A3 (en) 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
EP3171882A1 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using a cll-1 chimeric antigen receptor
US11542488B2 (en) * 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170274014A1 (en) 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014501A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase molecules and uses thereof
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
EP3183268B1 (en) 2014-08-19 2020-02-12 Novartis AG Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20250067191A (ko) * 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
WO2016061368A1 (en) 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
WO2016090034A2 (en) * 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) * 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN109476722A (zh) * 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
EP3350320A1 (en) 2015-09-17 2018-07-25 Novartis AG Car t cell therapies with enhanced efficacy
JP7082055B2 (ja) * 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
MX2018008106A (es) 2015-12-30 2019-03-14 Novartis Ag Terapias con celulas inmunoefectoras de una eficacia mejorada.
CN117866991A (zh) * 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CN109134660B (zh) * 2017-06-16 2022-07-01 上海恒润达生生物科技股份有限公司 靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
CA3090249A1 (en) * 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
JP7313642B2 (ja) * 2020-08-06 2023-07-25 ジャスミー株式会社 端末装置、情報処理システム及びプログラム

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022046476A (ja) * 2013-12-19 2022-03-23 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用

Also Published As

Publication number Publication date
CN106459989A (zh) 2017-02-22
MX2016008076A (es) 2016-08-12
RU2016129125A (ru) 2018-01-23
RU2714902C2 (ru) 2020-02-20
AU2021203547B2 (en) 2022-11-24
US20160311917A1 (en) 2016-10-27
CA3225456A1 (en) 2015-06-25
US20250011461A1 (en) 2025-01-09
SG11201604815RA (en) 2016-07-28
CA2931684C (en) 2024-02-20
JP6987945B2 (ja) 2022-01-05
EP3083964A4 (en) 2017-06-21
US11999794B2 (en) 2024-06-04
AU2014366047B2 (en) 2021-03-25
AU2021203547A1 (en) 2021-07-01
JP7797549B2 (ja) 2026-01-13
EP3083964B1 (en) 2022-01-26
JP2017500869A (ja) 2017-01-12
EP3083964A1 (en) 2016-10-26
BR112016013187A2 (pt) 2017-09-26
WO2015090230A1 (en) 2015-06-25
JP2022046476A (ja) 2022-03-23
US20240294662A1 (en) 2024-09-05
HK1224332A1 (zh) 2017-08-18
CA3225453A1 (en) 2015-06-25
EP4026909A1 (en) 2022-07-13
CN106459989B (zh) 2023-02-17
AU2014366047A1 (en) 2016-06-16
IL245764A0 (en) 2016-07-31
AU2024201926A1 (en) 2024-04-18
CN116478927A (zh) 2023-07-25
CA2931684A1 (en) 2015-06-25
US10640569B2 (en) 2020-05-05
AU2023200884B2 (en) 2024-05-09
ES2918501T3 (es) 2022-07-18
JP2021035948A (ja) 2021-03-04
US20200407460A1 (en) 2020-12-31
JP2023159154A (ja) 2023-10-31
TWI672379B (zh) 2019-09-21
TW201529850A (zh) 2015-08-01
AU2023200884A1 (en) 2023-05-11
JP2024050731A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
JP6987945B2 (ja) ヒトメソテリンキメラ抗原受容体およびその使用
US20240262884A1 (en) Treatment of cancer using gfr alpha-4 chimeric antigen receptor
JP7082055B2 (ja) 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
KR20160098259A (ko) 인간 메조텔린 키메라 항원 수용체 및 그의 용도
AU2024201926B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
HK40077678A (en) Human mesothelin chimeric antigen receptors and uses thereof
HK1224332B (en) Human mesothelin chimeric antigen receptors and uses thereof
BR122021024691B1 (pt) Usos de uma célula que expressa uma molécula car que se liga a cd19 em combinação com um ou mais inibidores de quinase
BR112016022798B1 (pt) Usos de células que expressam car19, método de produção de células que expressam car19, misturas reacionais, e composições e seus usos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201014

R150 Certificate of patent or registration of utility model

Ref document number: 6779785

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250